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Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients
with previously untreated chronic lymphocytic leukemia (CLL) have been limited.
METHODS

In a phase 3 trial, we randomly assigned (in a 2:1 ratio) patients 70 years of age or younger
with previously untreated CLL to receive either ibrutinib and rituximab for six cycles (after a
single cycle of ibrutinib alone), followed by ibrutinib until disease progression, or six cycles
of chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The primary
end point was progression-free survival, and overall survival was a secondary end point. We
report the results of a planned interim analysis.
RESULTS

A total of 529 patients underwent randomization (354 patients to the ibrutinib–rituximab
group, and 175 to the chemoimmunotherapy group). At a median follow-up of 33.6 months,
the results of the analysis of progression-free survival favored ibrutinib–rituximab over chemo
immunotherapy (89.4% vs. 72.9% at 3 years; hazard ratio for progression or death, 0.35; 95%
confidence interval [CI], 0.22 to 0.56; P<0.001), and the results met the protocol-defined
efficacy threshold for the interim analysis. The results of the analysis of overall survival also
favored ibrutinib–rituximab over chemoimmunotherapy (98.8% vs. 91.5% at 3 years; hazard
ratio for death, 0.17; 95% CI, 0.05 to 0.54; P<0.001). In a subgroup analysis involving patients
without immunoglobulin heavy-chain variable region (IGHV) mutation, ibrutinib–rituximab
resulted in better progression-free survival than chemoimmunotherapy (90.7% vs. 62.5% at
3 years; hazard ratio for progression or death, 0.26; 95% CI, 0.14 to 0.50). The 3-year progression-free survival among patients with IGHV mutation was 87.7% in the ibrutinib–rituxi
mab group and 88.0% in the chemoimmunotherapy group (hazard ratio for progression or
death, 0.44; 95% CI, 0.14 to 1.36). The incidence of adverse events of grade 3 or higher (regardless of attribution) was similar in the two groups (in 282 of 352 patients [80.1%] who
received ibrutinib–rituximab and in 126 of 158 [79.7%] who received chemoimmunotherapy), whereas infectious complications of grade 3 or higher were less common with
ibrutinib–rituximab than with chemoimmunotherapy (in 37 patients [10.5%] vs. 32 [20.3%],
P<0.001).
CONCLUSIONS

The ibrutinib–rituximab regimen resulted in progression-free survival and overall survival
that were superior to those with a standard chemoimmunotherapy regimen among patients
70 years of age or younger with previously untreated CLL. (Funded by the National Cancer
Institute and Pharmacyclics; E1912 ClinicalTrials.gov number, NCT02048813.)
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C

hronic lymphocytic leukemia (CLL)
is one of the most common lymphoid cancers, accounting for approximately 11%
of hematologic neoplasms. A marked improvement in progression-free survival and overall
survival among patients with CLL has been realized with the addition of anti-CD20 monoclonal
antibodies to purine nucleoside analogue or
alkylator-based chemotherapy.1,2 Phase 3 trials
have established the chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and
rituximab as the standard first-line treatment
for patients with CLL who are 70 years of age or
younger and who are suitable candidates for
such therapy after consideration of organ function and side-effect risks.1,3 The fludarabine–cyclophosphamide–rituximab combination appears to
be particularly effective in patients with immunoglobulin heavy-chain variable region (IGHV)–
mutated CLL, with roughly half the patients in
that subgroup remaining free from progression
up to 8 years after initial treatment.4-7 Although
fludarabine–cyclophosphamide–rituximab therapy is efficacious, it is associated with substantial toxic effects, including severe myelosuppression, a small risk of treatment-related
myelodysplasia, and infectious complications,
including opportunistic infections due to T-cell
immunosuppression.8
In parallel with advances in chemoimmunotherapy, elucidation of CLL B-cell biology has
identified new therapeutic targets.9 The interruption of leukemia proliferative signals mediated
through the B-cell receptor appears to be one of
the most promising approaches.10-12 Major effects
have been seen with ibrutinib, an irreversible
inhibitor of Bruton’s tyrosine kinase (BTK), a
B-cell signaling protein involved in B-cell development, differentiation, proliferation, and survival.10,13
Ibrutinib was initially found to have durable
efficacy in patients who had relapsed or refractory CLL.13,14 Subsequent phase 3 trials involving
previously untreated patients with progressive
CLL who were too frail to receive aggressive
therapy showed superior progression-free survival and overall survival with ibrutinib as compared with chlorambucil, which led to approval
of the drug by the Food and Drug Administration (FDA) as a first-line treatment option.15
However, data regarding the efficacy of ibrutinib
as a first-line treatment for patients 70 years of
age or younger with CLL, as compared with the
n engl j med 381;5

efficacious chemoimmunotherapy regimen of
fludarabine–cyclophosphamide–rituximab, have
been limited. We conducted a multicenter, openlabel, randomized, phase 3 trial (E1912) through
the National Clinical Trials Network (NCTN) to
evaluate the efficacy and safety of treatment
with ibrutinib in combination with six cycles of
rituximab, as compared with fludarabine–cyclophosphamide–rituximab, in previously untreated
patients with CLL who were 70 years of age or
younger.

Me thods
Trial Participants

Eligible participants were previously untreated
patients with CLL or the small lymphocytic lymphoma (SLL) subtype of CLL who were 70 years
of age or younger and who would be appropriate
candidates for treatment according to the International Workshop on Chronic Lymphocytic
Leukemia (IWCLL) Working Group criteria (see
the Supplementary Appendix, available with the
full text of this article at NEJM.org).16 Comprehensive eligibility criteria are listed in the Supplementary Appendix. Patients with chromosome
17p13 deletion were excluded from the trial because of the poor response of CLL in these patients to fludarabine–cyclophosphamide–rituxi
mab therapy.1,3,17
Trial Oversight

This trial was designed and coordinated by the
Eastern Cooperative Oncology Group–American
College of Radiology Imaging Network (ECOG–
ACRIN) Cancer Research Group in collaboration
with the other NCTN Cooperative Groups. The
trial protocol (available at NEJM.org) was approved by the National Cancer Institute (NCI)
central institutional review board and local institutional review boards as required by participating institutions. The trial was conducted in
accordance with the principles of the Declaration of Helsinki. Data that were gathered and
analyzed by trial investigators were entered into
an electronic database maintained by the ECOG–
ACRIN Biostatistical and Operations Office. The
trial was monitored twice annually by a standing
data and safety monitoring board that included
persons from both within and outside ECOG–
ACRIN. The authors reviewed and approved the
manuscript for submission for publication and
vouch for the accuracy and completeness of the
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data and for the adherence of the trial to the protocol. Ibrutinib was provided by Pharmacyclics
(a subsidiary of AbbVie) under a cooperative research and development agreement with the NCI.
Randomization and Treatment

After providing written informed consent, eligible
participants underwent randomization, which was
stratified according to the age of the patients
(<60 years vs. 60 to 70 years), ECOG performance-status score (0 or 1 vs. ≥2; scores are on
a 5-point scale, with higher numbers indicating
greater disability), Rai stage (0 to II [low or intermediate risk] vs. III or IV [high risk]), and the
presence or absence of chromosome 11q22.3
deletion on fluorescence in situ hybridization
analysis. Patients were randomly assigned in a
2:1 ratio to receive either ibrutinib–rituximab or
chemoimmunotherapy with fludarabine–cyclophosphamide–rituximab.
Patients who were randomly assigned to the
ibrutinib–rituximab group received ibrutinib (at
a dose of 420 mg per day until disease progression or an unacceptable level of side effects occurred) and rituximab (50 mg per square meter
of body-surface area on day 1 of cycle 2; 325 mg
per square meter on day 2 of cycle 2; and 500 mg
per square meter on day 1 of cycles 3 through 7);
each cycle was 28 days. Patients who were randomly assigned to the chemoimmunotherapy
group received six cycles of intravenous fludarabine (at a dose of 25 mg per square meter) and
cyclophosphamide (250 mg per square meter)
on days 1 through 3 with rituximab (50 mg per
square meter on day 1 of cycle 1; 325 mg per
square meter on day 2 of cycle 1; and 500 mg
per square meter on day 1 of cycles 2 through 6)
every 28 days. Full treatment information, including instructions regarding dose delays and
modifications, is provided in the Supplementary
Appendix.
Prophylaxis against Pneumocystis jirovecii (trimethoprim–sulfamethoxazole or alternative) and
herpes zoster (valacyclovir or alternative) was
given to patients in each group for 1 year after
treatment initiation. All patients received allopurinol (300 mg orally once daily) on days 1
through 14 of cycle 1. Patients treated with ibrutinib–rituximab also received allopurinol with
treatment cycle 2 (the first cycle that included
rituximab). Growth factor support was permitted
per guidelines of the American Society of Clinical Oncology (see the Supplementary Appendix).18
434
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Assessments of Safety and Response

All adverse events were graded according to the
NCI Common Toxicity Criteria, version 4. For the
purposes of dose modification, adverse events
involving platelet count and hemoglobin level
were graded according to the IWCLL CLL Working Group grading scale (see the Supplementary
Appendix).16
Responses were graded according to the 2008
IWCLL Working Group criteria that were in effect at the start of the trial16 along with the 2018
modification that included the category of complete response with incomplete bone marrow recovery19 (see the Supplementary Appendix). Isolated treatment-related lymphocytosis in the absence
of disease progression according to other criteria was not considered to indicate progression
until a nadir lymphocyte count was achieved.19,20
Bone marrow biopsies were performed at enrollment and at 12 months to assess response, with
central review by an expert hematopathologist
(see the Supplementary Appendix). Computed
tomographic (CT) scans of the chest, abdomen,
and pelvis were performed in all patients at enrollment and at the evaluation for response at 12
months. Minimal residual disease (MRD) was
assessed by means of peripheral-blood flow cytometry with a sensitivity greater than 1 CLL cell
per 10,000 leukocytes (see the Supplementary
Appendix). MRD assays were performed at the
time of the 12-month response evaluation and at
24 and 36 months after randomization.
Statistical Analysis

The primary end point was progression-free survival, which was defined as the time from randomization to documented CLL progression or
death without documented progression. Patients
alive without documented progression had their
data censored at the last disease assessment.
The trial was designed to have 80% power to
detect a hazard ratio for progression or death (in
the analysis of progression-free survival) of 0.67
(ibrutinib–rituximab vs. chemoimmunotherapy)
or less with the use of a stratified log-rank test
at the one-sided alpha level of 2.5%. The planned
enrollment was 519 patients, to be randomly assigned in a 2:1 ratio to receive ibrutinib–rituxi
mab or chemoimmunotherapy.
With input from the FDA, interim analyses
for progression-free survival were planned to
start at 24 to 27 months after full enrollment
and annually until either the efficacy boundary
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was crossed or full information (203 events of
progression or death) was reached. The prespecified boundary for the first interim analysis of progression-free survival was 2.807 on the
z-statistic scale, which corresponded to a onesided P value of 0.0025. A truncated version of
the O’Brien–Fleming boundary was to be used
subsequently.21 Futility rules for harm and inefficacy were included (see the Supplementary
Appendix).
Overall survival, which was defined as time
from randomization to death from any cause,
was a secondary end point and was to be tested
only if the result in the progression-free survival
analysis crossed the efficacy boundary. Patients
who were alive had their data censored at the
last date of contact. Interim analyses for overall
survival were to start when the efficacy boundary for progression-free survival was crossed and
to continue annually until early stopping criteria
were met or full information (125 deaths) was
reached. Critical values at each interim analysis
were to be determined with the use of the truncated O’Brien–Fleming boundary.
Stratified log-rank tests22 were used to compare time-to-event distributions. Hazard ratios
were estimated with the use of stratified Cox
proportional-hazards models.23 The frequency of
response and the incidence of adverse events
were compared between the two groups with the
use of Fisher’s exact test. Descriptive statistics
were used to summarize the characteristics of
the patients. Time-to-event distributions were
estimated with the use of the Kaplan–Meier
method. The primary analysis was conducted in
the intention-to-treat population, which included all the patients who had undergone randomization, regardless of eligibility or treatment
status. P values are two-sided, and 95% confidence intervals are presented.

R e sult s
Patients

From March 2014 through June 2016, the trial
enrolled 529 patients (Table 1). A total of 354
patients were assigned to the ibrutinib–rituximab
group, and 175 to the chemoimmunotherapy
group. A total of 19 patients did not start the
protocol-specified therapy (Fig. 1).
At a median follow-up of 33.6 months, 279 of
the 354 patients (78.8%) who had been randomly
assigned to receive ibrutinib–rituximab continued
n engl j med 381;5

ibrutinib therapy, and 132 of the 175 patients
(75.4%) who had been randomly assigned to receive chemoimmunotherapy continued to be monitored. The mean number of treatment cycles
among all the patients in the chemoimmunotherapy group who started therapy was five;
67.1% of these patients (106 of 158 patients) received six cycles. At the interim analysis, the
median duration of treatment in the ibrutinib–
rituximab group was 33.0 months (range, 1.0 to
54.0); 16.8% of the patients discontinued therapy
for reasons other than disease progression or
death (Table S10 in the Supplementary Appendix).
Efficacy

The first interim analysis was performed in September 2018. There were 77 events of progression
or death and 14 deaths (8 without progression).
The Kaplan–Meier estimates of progression-free
survival and overall survival are shown in Figures
2A and 3, respectively. At 3 years, the percentage
of patients with progression-free survival was
89.4% (95% confidence interval [CI], 86.0 to
93.0) in the ibrutinib–rituximab group, as compared with 72.9% (95% CI, 65.3 to 81.3) in the
chemoimmunotherapy group. The difference in
progression-free survival crossed the prespecified boundary (hazard ratio for progression or
death, 0.35; 95% CI, 0.22 to 0.56; P<0.001).
Overall survival was higher in the ibrutinib–
rituximab group than in the chemoimmunotherapy group (hazard ratio for death, 0.17; 95%
CI, 0.05 to 0.54; P<0.001). Overall survival at
3 years was 98.8% (95% CI, 97.6 to 100) in the
ibrutinib–rituximab group, as compared with
91.5% (95% CI, 86.2 to 97.0) in the chemoimmunotherapy group. Data regarding progressionfree survival and overall survival among eligible
patients who started the assigned treatment are
provided in the Supplementary Appendix.
In prespecified subgroup analyses of progression-free survival, ibrutinib–rituximab was superior to chemoimmunotherapy independent of age,
sex, or Rai stage and was also superior to
chemoimmunotherapy in the subgroup of patients with chromosome 11q22.3 deletion (Fig. 2C).
Ibrutinib–rituximab resulted in superior progression-free survival, as compared with chemoimmunotherapy, at 3 years among patients with IGHVunmutated CLL (90.7% vs. 62.5%; hazard ratio
for progression or death, 0.26; 95% CI, 0.14 to
0.50) (Fig. 2B). At the interim analysis, the difference in progression-free survival at 3 years
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Table 1. Characteristics of the Patients at Baseline (Intention-to-Treat Population).*

Characteristic

Ibrutinib–Rituximab
Group
(N = 354)

Chemoimmunotherapy
Group
(N = 175)

Total
(N = 529)

Age
Mean

56.7±7.5

56.7±7.2

56.7±7.4

145 (41.0)

70 (40.0)

215 (40.6)

Female

118 (33.3)

55 (31.4)

173 (32.7)

Male

236 (66.7)

120 (68.6)

356 (67.3)

11 (3.1)

9 (5.1)

20 (3.8)

Intermediate risk, I or II

187 (52.8)

94 (53.7)

281 (53.1)

High risk, III or IV

156 (44.1)

72 (41.1)

228 (43.1)

0

226 (63.8)

109 (62.3)

335 (63.3)

1

119 (33.6)

63 (36.0)

182 (34.4)

2

9 (2.5)

3 (1.7)

12 (2.3)

4.0±2.1

4.0±1.9

4.0±2.0

3.6

3.4

3.6

2.6–4.6

2.7–4.8

2.6–4.7

Chromosome 17p13 deletion‡

2 (0.6)

0

2 (0.4)

Chromosome 11q22.3 deletion

78 (22.0)

39 (22.3)

117 (22.1)

Trisomy 12

70 (19.8)

27 (15.4)

97 (18.3)

≥60 yr — no. (%)
Sex — no. (%)

Rai stage — no. (%)
Low risk, 0

ECOG performance-status score — no. (%)†

Beta2 microglobulin — mg/liter
Mean
Median
Interquartile range
Dohner classification — no. (%)

Normal
Chromosome 13q deletion
Other

69 (19.5)

37 (21.1)

106 (20.0)

121 (34.2)

58 (33.1)

179 (33.8)

14 (4.0)

14 (8.0)

28 (5.3)

70/280 (25.0)

44/115 (38.3)

114/395 (28.9)

210/280 (75.0)

71/115 (61.7)

281/395 (71.1)

IGHV mutation status — no./total no. (%)§
Mutated
Unmutated

*	Plus–minus values are means ±SD. Patients were randomly assigned to receive ibrutinib–rituximab or chemoimmunotherapy with fludarabine–cyclophosphamide–rituximab. Data include patients with small lymphocytic lymphoma (SLL);
overall, 11.4% of the patients (11.7% in the ibrutinib–rituximab group and 10.9% in the chemoimmunotherapy group)
had the SLL subtype of chronic lymphocytic lymphoma. Percentages may not total 100 because of rounding. More detailed information regarding the characteristics of the patients at baseline is provided in Table S1 in the Supplementary
Appendix.
†	Eastern Cooperative Oncology Group (ECOG) performance-status scores are assessed on a 5-point scale, with higher
scores indicating greater disability.
‡	Two patients with chromosome 17p13 deletion were enrolled and randomly assigned to the ibrutinib–rituximab group
but were later found to be ineligible on the basis of fluorescence in situ hybridization analysis.
§	Immunoglobulin heavy-chain variable region (IGHV) mutation status was tested in the 436 patients (82.4% of the overall population) who agreed to participate in the correlative study component of the trial and who provided a research
sample. Among the 436 patients who underwent testing, IGHV status could be determined in 395.
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529 Patients ≤70 yr of age with previously untreated
chronic lymphocytic leukemia were enrolled

354 Were assigned to receive
ibrutinib–rituximab and were included
in the primary analysis

175 Were assigned to receive
chemoimmunotherapy with
fludarabine–cyclophosphamide–
rituximab and were included
in the primary analysis

22 Were ineligible or did not start
assigned treatment
22 Were ineligible
17 Did not have translocation
(11;14) tested before
enrollment
3 Did not have GFR, aspartate
aminotransferase, or bilirubin
data within 14 days before
enrollment
2 Had chromosome 17p13
deletion
2 Did not start assigned treatment
owing to being ineligible

24 Were ineligible or did not start
assigned treatment
9 Were ineligible
9 Did not have translocation
(11;14) tested before
enrollment
17 Did not start assigned
treatment
14 Declined to participate
2 Were not covered by
insurance
1 Had medical reason

332 Were eligible and started assigned
treatment
352 Were included in the safety
analysis

151 Were eligible and started assigned
treatment
158 Were included in the safety
analysis

Figure 1. Enrollment, Randomization, and Follow-up.
All 529 patients who had been enrolled in the trial were included in the intention-to-treat analysis. Of the 529 patients
who underwent randomization, 31 (5.9%) were determined to have not met the eligibility criteria and were excluded
from the analysis of eligible patients who started assigned therapy (see the Supplementary Appendix). The safety
analysis included 510 patients who started the assigned protocol therapy. GFR denotes glomerular filtration rate.

among patients with IGHV-mutated CLL was not
significant (87.7% in the ibrutinib–rituximab
group and 88.0% in the chemoimmunotherapy
group; hazard ratio, 0.44; 95% CI, 0.14 to 1.36)
(Fig. S3A in the Supplementary Appendix).
The percentage of patients with an overall
response as determined by physical examination
was higher in the ibrutinib–rituximab group
(95.8%; 95% CI, 93.1 to 97.6) than in the chemo
immunotherapy group (81.1%; 95% CI, 74.5 to
86.6). With the inclusion of CT scan results and
central bone marrow review (when possible), the
incidence of complete response with or without
blood count normalization was lower in the
ibrutinib–rituximab group (17.2%; 95% CI, 13.4
to 21.6) than in the chemoimmunotherapy group
(30.3%; 95% CI, 23.6 to 37.7).
MRD in the peripheral blood at the 12-month
response assessment was evaluated in 276 of 354

n engl j med 381;5

patients (78.0%) who were treated with ibrutinib–rituximab and in 103 of 175 patients (58.9%)
who received chemoimmunotherapy with fludarabine–cyclophosphamide–rituximab. A lower
percentage of patients who were treated with
ibrutinib–rituximab (8.3%; 95% CI, 5.4 to 12.2)
than with chemoimmunotherapy (59.2%; 95%
CI, 49.1 to 68.8) were MRD-negative at cycle 12
(Fig. S1 in the Supplementary Appendix).
Safety

All adverse events of grade 3 or higher that were
reported in more than 2% of the patients in either group are summarized in Table 2. The incidence of adverse events of grade 3 or higher,
independent of attribution, was similar in the
two groups (in 282 of 352 patients [80.1%]
treated with ibrutinib–rituximab and in 126 of
158 patients [79.7%] who received chemoimmu-
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A Progression-free Survival among All Patients

80

72.9

70
60

Hazard ratio for progression or death,
0.35 (95% CI, 0.22–0.56)
P<0.001

40
30

Ibrutinib−rituximab
(37 events)
Chemoimmunotherapy
(40 events)

20
10
0

0

1

2

90.7

90

Percentage of Patients Free
from Progression

Percentage of Patients Free
from Progression

90

At 3 yr

100

89.4

50

m e dic i n e

B Progression-free Survival among Patients with IGHV-Unmutated CLL
At 3 yr

100

of

80
70

62.5

60

Hazard ratio for progression or death,
0.26 (95% CI, 0.14–0.50)

50
40
30

Ibrutinib−rituximab
(20 events)
Chemoimmunotherapy
(21 events)

20
10

3

0

4

0

1

2

Years
No. at Risk
Ibrutinib–rituximab
354
Chemoimmunotherapy 175

3

4

90
14

12
0

Years
No. at Risk

339
147

298
112

148
50

16
0

Ibrutinib–rituximab
210
Chemoimmunotherapy 71

203
64

177
43

C Subgroup Analysis
Subgroup
All patients
Eligible patients
Sex
Female
Male
Age
<60 yr
≥60 yr
ECOG performance-status score
0
1 or 2
Rai stage
0 to II
III or IV
Beta2 microglobulin level
Elevated
Normal
Splenomegaly
No
Yes
Lymphadenopathy
No
Yes
Dohner classification
Chromosome 11q22.3 deletion
Trisomy 12
Normal
Chromosome 13q deletion
IGHV mutation
Yes
No

No. of
Patients

No. of
Events

529
498

77
72

0.35 (0.22–0.56)
0.32 (0.20–0.51)

173
356

19
58

0.30 (0.12–0.77)
0.40 (0.23–0.67)

314
215

51
26

0.32 (0.18–0.56)
0.44 (0.20–0.97)

335
194

46
31

0.26 (0.14–0.47)
0.61 (0.29–1.27)

301
228

41
36

0.35 (0.18–0.65)
0.38 (0.19–0.74)

265
259

48
29

0.26 (0.14–0.48)
0.56 (0.26–1.20)

311
218

39
38

0.36 (0.19–0.70)
0.32 (0.17–0.63)

159
370

16
61

0.44 (0.14–1.42)
0.35 (0.21–0.59)

117
97
106
179

22
10
18
19

0.24 (0.10–0.62)
0.73 (0.19–2.89)
0.78 (0.29–2.04)
0.22 (0.08–0.60)

114
281

14
41

0.44 (0.14–1.36)
0.26 (0.14–0.50)

Hazard Ratio (95% CI)

0.12

0.25

0.50

1.00

Ibrutinib–Rituximab Better
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notherapy with fludarabine–cyclophosphamide–
rituximab, P = 0.91). There was a lower incidence
of grade 3 or 4 neutropenia in the ibrutinib–
rituximab group than in the chemoimmunotherapy group (90 patients [25.6%] vs. 71 [44.9%],
P<0.001), as well as a lower incidence of infectious complications, including neutropenic fever
(37 patients [10.5%] vs. 32 [20.3%], P = 0.005).
There was a higher incidence of grade 3 or 4
hypertension in the ibrutinib–rituximab group
than in the chemoimmunotherapy group (66 patients [18.8%] vs. 13 [8.2%], P = 0.002). Hemorrhagic events of grade 3 or higher occurred in
4 patients (1.1%) in the ibrutinib–rituximab
group (all grade 3 events) but in no patients in
the chemoimmunotherapy group (P = 0.32).
Cardiac toxic effects of grade 3 or higher occurred in 23 patients (6.5%) treated with ibrutinib–rituximab, including 13 cases of atrial fibrillation or atrial flutter, 3 cases of cardiac chest
pain, 2 cases of supraventricular tachycardia,
2 cases of heart failure (nonfatal), 2 cases of
pericardial effusion, 1 case of sinus bradycardia,
1 case of ventricular tachycardia, 1 case of cardiac arrest (nonfatal), and 1 case of myocardial
infarction. Cardiac toxic effects of grade 3 or
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At 3 yr
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90

91.5

80

Percentage of Patients

Figure 2 (facing page). Primary and Subgroup Analyses
of Progression-free Survival.
Panel A shows the Kaplan–Meier estimate of progression-free survival among all the patients who underwent
randomization. Panel B shows the Kaplan–Meier estimate of progression-free survival among patients whose
chronic lymphocytic leukemia (CLL) did not have the
immunoglobulin heavy-chain variable region (IGHV)
mutation. Panel C shows a forest plot of hazard ratios
for progression or death, according to prognostic subgroups of patients with CLL. The subgroup analysis
was conducted in the intention-to-treat population.
Hazard ratios (ibrutinib–rituximab vs. chemoimmunotherapy with fludarabine–cyclophosphamide–rituximab)
were estimated with the use of univariable Cox proportional-hazards models stratified according to the four
stratification factors. The size of the box is inversely
proportional to the variance of the hazard ratio estimates. The dashed line indicates the overall hazard
ratio among all patients who had undergone randomization. Eastern Cooperative Oncology Group (ECOG)
performance-status scores are assessed on a 5-point
scale, with higher scores indicating greater disability.
Rai stages of disease range from 0 (low risk) to I or II
(intermediate risk) to III or IV (high risk).

70
60

Hazard ratio for death,
0.17 (95% CI, 0.05–0.54)
P<0.001

50
40
30

Ibrutinib−rituximab
(4 deaths)
Chemoimmunotherapy
(10 deaths)

20
10
0

0

1

2

3

4

166
58

18
1

Years
No. at Risk
Ibrutinib–rituximab
354
Chemoimmunotherapy 175

347
155

318
130

Figure 3. Overall Survival (Intention-to-Treat Population).

higher occurred in 3 patients who received chemoimmunotherapy with fludarabine–cyclophosphamide–rituximab, including 2 cases of atrial
fibrillation and 1 case of acute coronary syndrome. Atrial fibrillation of any grade occurred
in 26 patients (7.4%) receiving ibrutinib–rituximab and in 5 patients (3.2%) receiving chemoimmunotherapy. One patient in the ibrutinib–
rituximab group had atrial fibrillation at
enrollment, which was exacerbated by ibrutinib
during cycle 1; the patient had sudden death 21
days after the start of cycle 2 of ibrutinib–rituximab therapy. A detailed summary of all adverse
events of grade 3 or higher that were attributed
by the treating physician to trial treatment is provided in Table S7 in the Supplementary Appendix.
Causes of death are listed in Table S6 in the
Supplementary Appendix. Among the 10 deaths
in the chemoimmunotherapy group, the cause
was CLL or therapy-related in the majority of
patients (4 deaths due to CLL, 2 due to therapyrelated acute myeloid leukemia, 1 due to lung
cancer, 1 due to metastatic colon cancer, 1 due to
drug overdose, and 1 due to infection). Among
the 4 deaths in the ibrutinib–rituximab group, the
cause was CLL in the minority of patients (1 death
due to CLL, 1 due to lung adenocarcinoma with
respiratory failure, 1 due to acute respiratory
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Table 2. Adverse Events of Grade 3 or Higher Reported in More Than 2% of Patients in Either Group.*
Event

Ibrutinib–Rituximab Group
(N = 352)
Grade 3

Grade 4

Chemoimmunotherapy Group
(N = 158)

Grade 5

Grade 3

Grade 4

Grade 5

0

number of patients (percent)
Hematologic event
Anemia

17 (4.8)

0

0

17 (10.8)

6 (3.8)

2 (0.6)

0

0

3 (1.9)

1 (0.6)

0

61 (17.3)

1 (0.3)

0

12 (7.6)

0

0

Lymphocyte count decreased

10 (2.8)

0

0

43 (27.2)

32 (20.3)

0

Lymphocyte count increased

77 (21.9)

0

0

12 (7.6)

0

0

Neutropenia

Hemolysis
Leukocytosis

38 (10.8)

52 (14.8)

0

35 (22.2)

36 (22.8)

0

Platelet count decreased

9 (2.6)

6 (1.7)

0

16 (10.1)

8 (5.1)

0

White-cell count decreased

7 (2.0)

1 (0.3)

0

35 (22.2)

23 (14.6)

0

Nonhematologic event
28 (8.0)

4 (1.1)

1 (0.3)

9 (5.7)

5 (3.2)

1 (0.6)

Febrile neutropenia

Infection†

8 (2.3)

0

0

21 (13.3)

4 (2.5)

0

Alanine aminotransferase
increased

6 (1.7)

2 (0.6)

0

1 (0.6)

0

0

Aspartate aminotransferase
increased

9 (2.6)

0

0

2 (1.3)

0

0

Hyperglycemia

12 (3.4)

2 (0.6)

0

8 (5.1)

0

0

Hyponatremia

11 (3.1)

0

0

3 (1.9)

0

0

9 (2.6)

2 (0.6)

0

1 (0.6)

1 (0.6)

0

Arthralgia

Atrial fibrillation

17 (4.8)

0

0

2 (1.3)

0

0

Hypertension

65 (18.5)

1 (0.3)

0

13 (8.2)

0

0

7 (2.0)

0

0

4 (2.5)

0

0

Fatigue
Maculopapular rash

11 (3.1)

0

0

8 (5.1)

0

0

Diarrhea

15 (4.3)

0

0

2 (1.3)

0

0

204 (58.0)

75 (21.3)

3 (0.9)

57 (36.1)

67 (42.4)

2 (1.3)

Any event, according to worst grade

*	Data include all adverse events of grade 3 or higher that occurred in more than 2% of the patients who started the assigned treatment in either group. Patients in the chemoimmunotherapy group received fludarabine–cyclophosphamide–
rituximab.
†	Infection included sepsis, sinusitis, skin infection, upper respiratory infection, urinary tract infection, infectious enterocolitis, lung infection, penile infection, scrotal infection, soft-tissue infection, lymph-gland infection, tooth infection,
kidney infection, and catheter-related infection.

failure, and 1 sudden death in a patient with some 17p13 deletion, ibrutinib–rituximab treathistory of atrial fibrillation).
ment was superior to chemoimmunotherapy with
fludarabine–cyclophosphamide–rituximab with
respect to progression-free survival and overall
Discussion
survival. Chemoimmunotherapy led to a higher
In this randomized trial involving patients 70 frequency of complete response and rendered
years of age or younger who had previously un- more patients MRD-negative than did ibrutinib–
treated CLL or SLL and did not have chromo- rituximab therapy. Nonetheless, the risk of pro-

440

n engl j med 381;5

nejm.org

August 1, 2019

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on August 18, 2019. For personal use only. No other uses without permission.
Copyright © 2019 Massachusetts Medical Society. All rights reserved.

Ibrutinib–Rituximab or Chemoimmunother apy for CLL

gression or death was 65% lower and the risk of
death was 83% lower with ibrutinib–rituximab
than with chemoimmunotherapy. The proportion
of patients who had an adverse event of grade 3
or higher was similar in the two groups.
Since fludarabine–cyclophosphamide–rituxi
mab is widely accepted as an effective chemoimmunotherapy regimen for patients with CLL, the
improvements in both progression-free survival
and overall survival that were observed with six
cycles of ibrutinib–rituximab followed by continuous ibrutinib therapy, as compared with the
6-month course of chemoimmunotherapy, are
notable.1,3-7 Three previous trials have shown a
survival advantage with one therapy over another
among patients with previously untreated CLL.1,2,15
The advantage of six cycles of ibrutinib–rituxi
mab followed by continuous ibrutinib therapy
with regard to these end points exceeded the
prespecified thresholds for superiority at the
time of the first interim analysis, despite the fact
that the progression-free survival and overall
survival observed among patients treated with
fludarabine–cyclophosphamide–rituximab was
similar to or better than that anticipated on the
basis of historical studies (Table S9 in the Supplementary Appendix).1,3 Since the current advantage with regard to overall survival was based on
a limited number of events, the long-term followup for survival among the patients in this trial,
as well as for the incidence of myelodysplastic
syndrome or acute myeloid leukemia, second
cancers, and infectious complications, will be
important.
Ibrutinib–rituximab resulted in superior progression-free survival in high-risk subgroups, including patients with Rai stage III or IV disease,
chromosome 11q22.3 deletion, and unmutated
IGHV. Chemoimmunotherapy with fludarabine–
cyclophosphamide–rituximab has proved to be
particularly effective in patients with IGHV-mutated
CLL,5,6 with roughly half the patients in this
lower-risk subgroup remaining in remission 8 to
10 years after the initiation of treatment.7 Longer
follow-up in this subgroup of patients will provide additional clinical insights.
The safety results regarding ibrutinib–rituxi
mab therapy in the E1912 trial were consistent
with the results of previous trials of ibrutinibbased therapy.13-15 The risk of atrial fibrillation of
any grade was 7.4% in the ibrutinib–rituximab

n engl j med 381;5

group. The recently reported Alliance 041202
trial, which tested first-line ibrutinib–rituximab
therapy and ibrutinib monotherapy, showed that
the incidence of atrial fibrillation in these two
groups was 14% and 17%, respectively, among
patients with CLL who were 65 years of age or
older (median age, 71 years).24 An age of 65 years
or older, history of hypertension, and history of
atrial fibrillation are risk factors for the development of atrial fibrillation during ibrutinib treatment,25 which suggests that the lower incidence
of cardiac complications in the E1912 trial may
be due to the younger patient population (median age, 58 years) relative to a pooled analysis
of patients participating in other trials (median
age, 67 years).25 Unexplained or unwitnessed death,
which can be due to cardiac arrhythmias, was
observed in only 1 patient in the E1912 trial, as
compared with 11 of 361 patients (3%) treated
with ibrutinib in the Alliance 041202 trial.24 Grade
3 or 4 hypertension in patients who were treated
with ibrutinib–rituximab in the E1912 trial also
occurred at a lower frequency than that seen
among patients in the Alliance 041202 trial
(18.8% vs. 34%).24 Major hemorrhagic events (all
grade 3) occurred in 1.1% of the patients in the
ibrutinib–rituximab group, with no fatal events.
As of the interim analysis, one case of nonfatal
cardiac arrest has been observed in the E1912
trial. Given the long-term, indefinite use of ibrutinib, we continue to monitor this end point closely.
The superior overall survival with ibrutinibbased therapy that was observed in the E1912
trial but not in the Alliance 041202 trial is notable because the chemoimmunotherapy that was
used in the E1912 trial is more efficacious than
the chemoimmunotherapy used in the Alliance
trial.3 Several possible factors may contribute to
these findings. First, more efficacious therapy
may contribute more to survival prospects in
younger patients with CLL with fewer coexisting
conditions, who are less likely than older patients
to die from unrelated causes. Second, more severe treatment-related toxic effects, including an
increased risk of sudden death among older patients, may offset decreases in disease-related
mortality among older patients. The higher mortality among patients receiving active treatment
in the Alliance trial (7% of patients treated with
ibrutinib–rituximab) relative to the participants
in the E1912 trial (1%) and reported outcomes in
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a study in non-Hodgkin’s lymphoma subtypes
support this notion.26
Although all the ibrutinib-treated patients in
the E1912 trial also received rituximab, the bene
fits of combining rituximab with ibrutinib are
unclear. No differences in progression-free survival or overall survival between the ibrutinibalone group and the ibrutinib–rituximab group
in the Alliance 041202 trial have been observed
to date,24 a finding that is consistent with the
results of a randomized comparison of ibrutinib
alone and ibrutinib–rituximab in a trial predominantly involving patients with relapsed CLL.27 It is
unclear whether these findings can be extrapolated to patients 70 years of age or younger with
previously untreated CLL.
In conclusion, among patients 70 years of age
or younger with previously untreated CLL, the
combination of six cycles of ibrutinib–rituximab
therapy followed by ibrutinib given continuously
until relapse resulted in progression-free survival
and overall survival that were superior to those
with 6 months of chemoimmunotherapy with
fludarabine–cyclophosphamide–rituximab. However, indefinite use of ibrutinib therapy has been
associated with substantial expense28 and the
potential for long-term toxic effects and may
increase the risk of clonal selection leading to
drug resistance.29,30
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